EQ/T. Rowe Price Health Sciences Portfolio
Data updated: 2026-08-25
C000203168 — EQ/T. Rowe Price Health Sciences Portfolio. United States Large Cap Blend / Core Health Care Equity. Holdings, fees, performance and SEC filings.
C000203168 Fund Overview
EQ/T. Rowe Price Health Sciences Portfolio is a US mutual fund managed by Eq Advisors Trust, categorised as United States Large Cap Blend / Core Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Eq Advisors Trust
- Category: United States Large Cap Blend / Core Health Care Equity
- Assets under management: $176.60M
- 1-year return: 32.0%
- SEC CIK: 0001027263
- SEC series ID: S000062644
- Share class ID: C000203168
C000203168 Investment Objective and Strategy
EQ/T. Rowe Price Health Sciences Portfolio describes its objective and strategy as follows, from its latest prospectus filed with the SEC by Eq Advisors Trust.
Investment objective
Seeks to achieve long-term capital appreciation.
Principal investment strategy
Under normal circumstances, the Portfolio invests at least 80% of its net assets, plus any borrowings for investment purposes, in securities of companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences (collectively termed health sciences). The Portfolio defines the health sciences industry broadly and divides it into four main areas: pharmaceutical companies; health care services companies; medical products and devices providers; and biotechnology firms. The Portfolios allocation among these four areas will vary depending on the relative potential the Sub-Adviser sees within each area and the outlook for the overall health sciences sector. While the Portfolio can invest in companies of any size, the majority of the Portfolios assets are expected to be invested in large- and mid-capitalization companies.
The Portfolio is non-diversified, which means that it may invest a greater portion of its assets in the securities of one or more issuers and invests overall in a smaller number of issuers than a diversified portfolio. The Sub-Adviser will use fundamental, bottom-up analysis that seeks to identify high-quality companies and the most compelling investment opportunities. In general, the Portfolio will follow a growth investment strategy, seeking companies whose earnings are expected to grow faster than inflation and the economy in general. However, when stock valuations seem unusually high, a value approach, which gives preference to seemingly undervalued companies, may be emphasized. The Portfolio generally seeks investments in companies that are developing new and effective medicines, as well as companies whose business models reduce costs or improve quality in health care systems.
In pursuing the Portfolios investment objective, the Sub-Adviser has the discretion to deviate from its normal investment criteria. These situations might arise when the Sub-Adviser believes a security could increase in value for a variety of reasons, including an extraordinary corporate event, a new product introduction or innovation, a favorable competitive development, or a change in management. While most assets will typically be invested in U.S. common stocks, the Portfolio may invest in foreign stocks, including emerging market stocks, and options (which are derivative transactions) in keeping with the Portfolios objectives. The Portfolio may write call and put options primarily as a means of generating additional income. Normally, the Portfolio will own the securities on which it writes call or put options.
The premium income received by writing covered calls can help reduce but not eliminate portfolio volatility. The Portfolio may sell securities for a variety of reasons, such as to secure gains, limit losses, or redeploy assets into more promising opportunities. The Portfolio also may lend its portfolio securities to earn additional income.
C000203168 Holdings
Top 10 holdings of EQ/T. Rowe Price Health Sciences Portfolio by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Eli Lilly & Co. | 14.34% |
| Johnson & Johnson | 6.34% |
| UnitedHealth Group, Inc. | 5.98% |
| AbbVie, Inc. | 5.31% |
| Merck & Co., Inc. | 4.25% |
| Gilead Sciences, Inc. | 2.96% |
| Thermo Fisher Scientific, Inc. | 2.67% |
| Vertex Pharmaceuticals, Inc. | 2.39% |
| Bristol-Myers Squibb Co. | 2.24% |
| Abbott Laboratories | 2.01% |
C000203168 Portfolio Allocation
Asset-class allocation of EQ/T. Rowe Price Health Sciences Portfolio by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.5% |
| Cash & Equivalents | 1.5% |
C000203168 Performance
Total returns for C000203168 (as of 2026-10-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 7.3% |
| 1 year | 32.0% |
| 3 years (annualised) | 10.0% |
| 5 years (annualised) | 3.6% |
C000203168 Risk Information
Risk metrics for C000203168, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 16.4%
C000203168 Costs and Fees
C000203168 costs about $120 per $10,000 invested per year in fund expenses.
- Net expense ratio: 1.20%
- Gross expense ratio: 1.37%
- Portfolio turnover: 42%
- Brokerage commissions: 2.87 bps of average net assets (SEC N-CEN)
C000203168 Cashflows
Over the 12 months to 2026-06, EQ/T. Rowe Price Health Sciences Portfolio had net outflows of $19.32M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-06 | −$765.79K |
| 2026-05 | −$1.94M |
| 2026-04 | −$2.02M |
| 2026-03 | −$1.25M |
| 2026-02 | −$2.31M |
| 2026-01 | −$3.03M |
C000203168 Debt Constituents
No individual debt constituents are reported in EQ/T. Rowe Price Health Sciences Portfolio's latest SEC N-PORT filing.
C000203168 Prospectus and SEC Filings
Official EQ/T. Rowe Price Health Sciences Portfolio filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2025-04-28
- Prospectus (485BPOS) — filed 2024-04-26
- Prospectus (485BPOS) — filed 2023-04-26
- Portfolio holdings (N-PORT) — filed 2026-08-25
- Portfolio holdings (N-PORT) — filed 2026-05-26
- Portfolio holdings (N-PORT) — filed 2026-02-27
- Annual census (N-CEN) — filed 2026-03-11
- Annual census (N-CEN) — filed 2025-03-10
Related Funds
Other United States Large Cap Blend / Core Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.